BRIEF-Acelrx Announces Rebranding With Name Change To Talphera Inc

Reuters
09 Jan 2024

Jan 9 (Reuters) - AcelRx Pharmaceuticals Inc :

* ACELRX ANNOUNCES REBRANDING WITH NAME CHANGE TO TALPHERA, INC.

* ACELRX PHARMACEUTICALS INC - TALPHERA WILL BEGIN TRADING ON NASDAQ UNDER TRADING SYMBOL "TLPH" EFFECTIVE JANUARY 10

* ACELRX PHARMACEUTICALS - CO'S LEAD NAFAMOSTAT PRODUCT CANDIDATE, NIYAD, IS EXPECTED TO HAVE A PREMARKET APPROVAL SUBMISSION TO FDA IN H2 OF 2024

* ACELRX PHARMACEUTICALS INC - FIRST PATIENT IS EXPECTED TO BE ENROLLED FOR NEPHRO STUDY IN Q1 OF 2024

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10